{
  "links": "https://www.ycombinator.com/companies/parcelbio",
  "name": "ParcelBio",
  "headline": "Next-generation mRNA medicines",
  "batch": "W24",
  "description": "ParcelBio is delivering the next generation of RNA medicines.",
  "activity_status": "Active",
  "website": "https://parcelbio.com/",
  "founded_date": 2023.0,
  "team_size": 5.0,
  "location": "San Francisco",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:gene-therapy; industry:biotech; industry:healthcare; industry:drug-delivery; industry:therapeutics; location:san-francisco-bay-area",
  "founders": [
    {
      "name": "David Weinberg, Founder",
      "description": "David is the co-founder and CEO of ParcelBio. He was previously VP of RNA Platform at Orbital Therapeutics / Circ Bio, where he led the development of a circular RNA therapeutics platform. Before that, he was Sr. Director of Molecular Research at Freenome, where he built the multiomics diagnostics platform that enabled a blood test for the early detection of cancer​. David obtained his PhD from MIT, was a UCSF Faculty Fellow, and has been honored with Forbes ‘30 Under 30’ and an NIH DP5 Award.",
      "linkedin": "https://linkedin.com/in/david-e-weinberg"
    },
    {
      "name": "Chris Carlson, Founder",
      "description": "Chris is the co-founder and CSO of ParcelBio. He was previously a scientist at Orbital Therapeutics, where he was the primary contributor on multiple patents regarding stabilization of therapeutic RNAs. Chris obtained his PhD from UCSF where he studied RNA packaging and protection in viruses.",
      "linkedin": "https://linkedin.com/in/christopher-carlson-"
    }
  ],
  "status": true,
  "markdown": "raw_markdown='[ 0 ](https://parcelbio.com/</cart>)\\n[ Skip to Content ](https://parcelbio.com/<#page>)\\n[ ![ParcelBio](https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/e65153ef-f2a9-4366-99bc-9049b288a0e6/Original+Logo+Symbol.png?format=1500w) ](https://parcelbio.com/</>)\\n[ ![ParcelBio](https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/f63a3055-db22-475b-a5d2-743b0958e727/Original+Logo+Symbol.png?format=1500w) ](https://parcelbio.com/</>)\\n[ Home ](https://parcelbio.com/</>)\\nOpen Menu Close Menu\\n[ ![ParcelBio](https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/e65153ef-f2a9-4366-99bc-9049b288a0e6/Original+Logo+Symbol.png?format=1500w) ](https://parcelbio.com/</>)\\n[ ![ParcelBio](https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/f63a3055-db22-475b-a5d2-743b0958e727/Original+Logo+Symbol.png?format=1500w) ](https://parcelbio.com/</>)\\n[ Home ](https://parcelbio.com/</>)\\nOpen Menu Close Menu\\n[ Home  ](https://parcelbio.com/</>)\\n![](https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/cfc81f4f-0f3d-4afb-992a-419b20a7895b/Transparent+Logo.png)\\n#### Delivering the next generation of RNA medicines\\nContact Us \\n' markdown_with_citations=' 0 ⟨1⟩\\n Skip to Content ⟨2⟩\\n ![ParcelBio⟨3⟩ ](https://parcelbio.com/</>)\\n ![ParcelBio⟨4⟩ ](https://parcelbio.com/</>)\\n Home ⟨5⟩\\nOpen Menu Close Menu\\n ![ParcelBio⟨3⟩ ](https://parcelbio.com/</>)\\n ![ParcelBio⟨4⟩ ](https://parcelbio.com/</>)\\n Home ⟨5⟩\\nOpen Menu Close Menu\\n Home  ⟨5⟩\\n![](https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/cfc81f4f-0f3d-4afb-992a-419b20a7895b/Transparent+Logo.png)\\n#### Delivering the next generation of RNA medicines\\nContact Us \\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://parcelbio.com/</cart>:  0 \\n⟨2⟩ https://parcelbio.com/<#page>:  Skip to Content \\n⟨3⟩ https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/e65153ef-f2a9-4366-99bc-9049b288a0e6/Original+Logo+Symbol.png?format=1500w:  ![ParcelBio\\n⟨4⟩ https://images.squarespace-cdn.com/content/v1/659862002ec0432282e136ef/f63a3055-db22-475b-a5d2-743b0958e727/Original+Logo+Symbol.png?format=1500w:  ![ParcelBio\\n⟨5⟩ https://parcelbio.com/</>:  Home \\n' fit_markdown='' fit_html=''",
  "generated_description": "**ParcelBio: Pioneering Next-Gen RNA Medicines**\n\nFounded in 2023 and situated in the heart of San Francisco, ParcelBio is part of Y Combinator's Batch W24 and is making waves in the biotech scene. Their mission is straightforward yet ambitious: to deliver the next generation of RNA medicines. This focus places them at the frontier of gene therapy and therapeutics, making them a company to watch in the healthcare ecosystem.\n\nCurrently, ParcelBio operates with a nimble team of just five employees, fostering a startup culture that encourages innovation and agility. They are supported in their journey by their Group Partner, nan, which hints at a network that could enhance their growth and visibility in a competitive landscape.\n\nTheir expertise is tagged under several key areas, including gene therapy, drug delivery, and overall biotech development. This multifaceted approach suggests they’re not just working on a single product but are developing a platform that could eventually transform how RNA medicines are delivered and function.\n\nYou can learn more about their efforts and explore their work through their website at [ParcelBio.com](https://parcelbio.com/). If you're intrigued by the future of healthcare and the potential of mRNA therapies, ParcelBio is definitely a name to keep an eye on."
}